Recruiting

NCT Number: NCT07388615

The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children

This study aims to:

1. To evaluate the effectiveness of Immulant ® addition to standard treatment in reducing clinical symptoms of Cryptosporidiosis in immunocompromised children. 2. To measure the changes in parasite count in stool samples after treatment with Immulant ®. 3. To assess the safety and tolerability of Immulant ® in children participating in the study.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cryptosporidium Infection Animal Diseases Coccidiosis Cryptosporidiosis Digestive System Diseases Gastrointestinal Diseases Infections Intestinal Diseases Intestinal Diseases, Parasitic Parasitic Diseases Parasitic Diseases, Animal Protozoan Infections Protozoan Infections, Animal

Age range

5 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

National Nutritional Institute

Cairo, 11731, Egypt

Location status: Recruiting

Location contact

National Nutritional Institute

CONTACT

[email protected]

02-01147491425

About this study

The present prospective study will be (open labelled) Randomized Clinical Trial and was approved by the Research Ethical Committee Of national nutritional institute. Oral and written consent will be obtained from all patients and controls after a full explanation of the study.

A total of at least 60 immunocompromised children consecutively diagnosed with cryptosporidiosis were recruited from the outpatient clinic of National Nutritional Institute.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical diagnosis of Cryptosporidiosis Disease
Age from 5-12 years
Immunocompromised children
Not receiving any drugs causing immunosuppression

Exclusion criteria

Patients undergoing organ transplantation
Patients suffering from autoimmune diseases.
Patients suffering from hypersensitivity of this plant extract

Treatment and study plan

Echinacea Extract

Drug

Immulant ® (an extract derived from Echinacea purpurea plant)

Primary outcomes

To measure the changes in parasite count in stool samples after treatment

Time frame: six months

Study contacts

Contact information is provided by the study sponsor or research team.

Salah

CONTACT

[email protected]

02+01147491425

Sponsors and collaborators

Lead sponsor

Al-Azhar University

Other

Registry information

Important dates

Study start: 2026
Primary completion: 2026
Study completion: 2026
First posted: Feb 5, 2026
Registry last updated: Feb 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting